NCT02943902View on ClinicalTrials.gov

Reduced PCV Dosing Schedules in South African Infants

PHASE3CompletedINTERVENTIONAL
Enrollment

600

Participants

Timeline

Start Date

January 9, 2017

Primary Completion Date

February 26, 2019

Study Completion Date

February 26, 2019

Conditions
PneumoniaMeningitis
Interventions
BIOLOGICAL

Pneumococcal conjugate vaccine (PCV10 ) 1+1, 6 weeks

PCV10 1+1, 6 weeks \& 9 months

BIOLOGICAL

Pneumococcal conjugate vaccine (PCV10 ) 1+1, 14 weeks

PCV10 1+1, 14 weeks \& 9 months

BIOLOGICAL

Pneumococcal conjugate vaccine (PCV10 ) 2+1

PCV10 2+1, 6\&14 weeks \& 9 months

BIOLOGICAL

Pneumococcal conjugate vaccine (PCV13 ) 1+1, 6 weeks

PCV13 1+1, 6 weeks \& 9 months

BIOLOGICAL

Pneumococcal conjugate vaccine (PCV13 ) 1+1, 14 weeks

PCV13 1+1, 14 weeks \& 9 months

BIOLOGICAL

Pneumococcal conjugate vaccine (PCV13 ) 2+1

PCV13 2+1, 6\&14 weeks \& 9 months

Trial Locations (2)

2055

Nrf/Dst Vpd Rmpru, Soweto

Unknown

Chris Hani Baragwanath Academic Hospital, Johannesburg

All Listed Sponsors
collaborator

University College, London

OTHER

lead

University of Witwatersrand, South Africa

OTHER

NCT02943902 - Reduced PCV Dosing Schedules in South African Infants | Biotech Hunter | Biotech Hunter